Previous 10 | Next 10 |
2024-03-19 15:51:38 ET More on Atossa Therapeutics Atossa spikes as H.C. Wainwright starts at Buy on lead asset Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therap...
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patien...
2024-03-18 08:40:31 ET More on Atossa Therapeutics Atossa spikes as H.C. Wainwright starts at Buy on lead asset Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therap...
SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast ca...
SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic (PK) run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study will be presented at the American Association for Cancer ...
2024-02-12 13:27:38 ET More on Atossa Therapeutics Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therapeutics Read the full article on Seeking Alpha For fur...
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that the (Z)-endoxifen arm of the o...
SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad...
SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that it has reached full enrollment...
2023-11-13 14:26:06 ET More on Atossa Therapeutics Atossa Therapeutics: Betting Big On Transforming Old Breast Cancer Care Atossa stock jumps 16% in wake of Cantor overweight rating Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earning...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s ...